<DOC>
	<DOCNO>NCT00113776</DOCNO>
	<brief_summary>The purpose study examine safety ABX-EGF administer monotherapy subject metastatic colorectal cancer previously randomize best supportive care ( BSC ) protocol 20020408 subsequently determine progressive disease .</brief_summary>
	<brief_title>Evaluating ABX-EGF Extended Therapy Subjects With MetastaticColorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject previously randomize BSC protocol 20020408 subsequently determine progressive disease ECOG performance status 0 , 1 2 Adequate hematologic , renal hepatic function Myocardial infarction time interval complete 20020408 enrollment study History evidence interstitial pneumonitis pulmonary fibrosis Prior antitumor therapy include prior experimental agent approve antitumor small molecule biologics time interval complete 20020408 protocol enrollment study Use systemic chemotherapy radiotherapy time interval complete 20020408 protocol enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Metastatic Colorectal Cancer , Colon</keyword>
	<keyword>Colorectal , Rectal Cancer , EGFr</keyword>
	<keyword>Metastatic , Cancer , ABX-EGF</keyword>
	<keyword>Panitumumab , Clinical Trial</keyword>
	<keyword>Immunex , Abgenix , Amgen</keyword>
</DOC>